Alembic Pharmaceuticals Limited · NSE:APLLTD
Alembic Pharmaceuticals — Q1 FY23 Earnings Presentation
14 slides from Alembic Pharmaceuticals's earnings presentation, June 2022
Slide 1: Alembic Pharmaceuticals Limited Investor presentation – June 2022
Alembic Pharmaceuticals Limited Investor presentation – June 2022 BSE & NSE: APLLTD 1
Slide 2: Milestones
Milestones 1907 Established by Amin family 2006 FDA approves API facility 2007 Acquired Dabur’s Indian Cardiology, GI and Gynaecology brands 2008 FDA approves Formulation facility 2009 Multiple divisions to address chronic therapies launched 2010 Pharmaceuticals business demerged from Alembic – APL
Slide 3: Financial Highlights
Financial Highlights INR Bn Particulars Q1 FY23 Q1 FY22 Growth FY22 Net Sales 12.62 13.26 -5% 53.06 EBIDTA Pre R&D 2.43 4.06 -40% 16.64 Margin % 19% 31% 31% R&D 2.61 1.67 56% 8.38 R&D % 21% 13% 16% EBIDTA Post R&D 0.09 2.54 -97% 9.55 Margin % 1% 19% 18% Net Profit* -0.66 1.65 5.46 Capex 1.01 1.24 4.
Slide 4: Acquisition of Aleor
Acquisition of Aleor Summary : Alembic Pharmaceuticals had acquired the balance Q1FY23 Financial Highlights with and without Aleor’s one time 40% stake in Aleor Dermaceuticals from its JV Partner Orbicular impact INR Bn Pharmaceutical Technologies in Q4FY22. With this, Aleor Dermaceuticals has becom
Slide 5: Revenue snapshot – Q1FY23
Revenue snapshot – Q1FY23 INR Bn Key Highlights : Business Q4FY22 Q1FY23 Q1FY22 Y-o-Y Q-o-Q India Branded Business : Recorded flat growth with topline of Rs 480 Formulations crores for Q1FY23, reflecting performance better than the industry. Speciality India 4.49 4.80 4.81 0% 7% segment grew by 23%
Slide 6: US Generic
US Generic INR Bn Revenue – Q1 FY23 INR Bn Revenue – Last 5 Years CAGR - 16% 21.63 19.76 3.69 0% i 3.67 16.66 12.88 9.20 Q1FY22 Q1FY23 FY18 FY19 FY20 FY21 FY22 Approved ANDAs Injectable Derma 2 Inhalation 22 2 ➢ Well-established US front end having strong customer base ➢ Revenue in US business remai
Slide 7: Ex-US Generics
Ex-US Generics Revenue : Q1 FY23 INR Bn Revenue – Last 5 Years INR Bn CAGR - 28% 1.97 1.82 7.79 7.75 4.94 4.97 Q1FY22 Q1FY23 ➢ The Ex-US business posted de-growth of 8% and 3% compared to Q1FY22 and Q4FY22, respectively. 2.86 ➢ Ex-US driven by partnership ➢ Presence in following markets - Europe, Ca
Slide 8: API
API Revenue : Q1 FY23 INR Bn Revenue – Last 5 Years INR Bn 2.79 CAGR - 10% 2.33 9.55 9.39 7.71 7.08 6.51 Q1FY22 Q1FY23 ➢ De-growth of 16% on QoQ basis is mainly on account of volume dip compared to Q1FY22. ➢ API Business posted growth of 5% on Sequential quarter basis. ➢ 1 USDMFs filed in Q1FY23. 12
Slide 9: R&D: Significant investments in building capabilities
R&D Significant 10.0 investments in building capabilities INR Bn ANDA – Accelerated filings & approvals 15.8% 37 Filing 8.0 14.0% Approval 13.1% 12.7% 29 30 29 12.4% 6.0 25 R&D Spend 23 20 21 18 19 4.0 8.4 11 Filings & 6.7 7 Approvals 6.5 R&D % of were 5.0 sales 2.0 4.1 contributed by acquisition of
Slide 10: State of the art facilities and infrastructure
State of the art facilities and infrastructure Audit/Filing Location Dosage Form status International Generics F1 – Panelav General Oral Solids Mar’20* Oncology Oral Solids Jun’19* F2 – Panelav Oncology Injectables Feb’21# F2 - Panelav F3 - Karkhadi General Injectables F3 – Karkhadi Ophthalmic Nov’2
Slide 11: Branded Business
Branded Business Revenue – Q1 FY23 INR Bn Revenue – Last 5 Years CAGR - 11% INR Bn 19.3 4.81 0% i 4.80 0.53 0.72 15.0 13.8 14.3 Vet 1.18 1.92 12.7 Acute Speciality 2.90 2.36 Q1FY22 Q1FY23 FY18 FY19 FY20 FY21 FY22 Marketing organization Key achievements ➢ 5500 + Marketing team ➢ India Branded Busines
Slide 12: Therapy-wise Performance Q1 FY23
Therapy-wise Performance Q1 FY23 Q1 FY23 Q1 FY22 Therapy Market Alembic Alembic Therapy Market Alembic Alembic Therapy Growth Share % Growth % Growth % Growth Share Growth % Growth % % (ORG) (ORG) (ORG) (PRIM) % (ORG) % (ORG) (ORG) (PRIM) Cardiology -0 1.9 10 11 20 1.7 8 13 Gastrology 12 1.3 9 11 35
Slide 13: Financials : Generating consistent returns
Financials : Generating consistent returns Revenue INR Bn EBIDTA Net Profit INR Bn INR Bn 53.93 53.06 16.31 11.78 46.06 39.35 12.13 8.29 31.31 10.78 # 6.90 # 8.75 5.84 6.42 4.13 FY18 FY19 FY20 FY21 FY22 FY18 FY19 FY20 FY21 FY22 FY18 FY19 FY20 FY21 FY22 CAGR - 14% CAGR - 14% CAGR - 14% EBIDTA margin
Slide 14: Thank you
Thank you Safe Harbour Agreement: Materials and information provided during this presentation may contain ‘forward-looking statements’. These statements are based on current expectations, forecasts and assumptions that are subject to risks and uncertainties which could cause actual outcomes and resu
Alembic Pharmaceuticals — Q1 FY23 Earnings Presentation on 6ix